Company Overview
Snapshot
Founded in December 2015 by Gilad Litvin and Almog Aley-raz, CorNeat Vision operates with 11–50 employees. The company has raised $18.77 million across 7 funding rounds from 2 investors. In August 2021, the company secured funding from Guangzhou Sino-Israel Biotech Investment Fund (GIBF).
Business overview
CorNeat Vision is a medical device company focused on developing and marketing permanent, tissue-integrating implants. Its core technology, CorNeat EverMatrix™, is designed to overcome the foreign body response typically triggered by implants, allowing seamless and permanent integration with live tissue without inflammation. This technology aims to replace harvested human and animal tissues used in various surgical procedures across diverse medical fields, operating within the Health Tech & Life Sciences sector.
Strategic signal
In June 2023, CorNeat Vision received FDA approval for its non-degradable synthetic eye tissue. This regulatory milestone signals significant progress in bringing advanced ophthalmic solutions to market and validates the company's innovative biomaterial technology, positioning it for broader clinical adoption and commercialization in the medical device industry.
Log in to access full profile ›Company Intelligence Q&A
- What is CorNeat Vision's primary technological innovation?
- CorNeat Vision's primary technological innovation is CorNeat EverMatrix™, a platform material designed for permanent and seamless integration with live tissue without triggering an inflammatory response, thereby overcoming a major challenge in implantable medical devices.
- When did CorNeat Vision complete its pre-clinical phase for synthetic cornea and scleral patch?
- CorNeat Vision completed the pre-clinical phase for its synthetic cornea and scleral patch in September 2019.
- What significant regulatory approval did CorNeat Vision receive in 2023?
- In June 2023, CorNeat Vision received FDA approval for its non-degradable synthetic eye tissue, marking a key regulatory milestone for its innovative medical devices.
- Which investor participated in CorNeat Vision's August 2021 funding round?
- In August 2021, CorNeat Vision secured funding from Guangzhou Sino-Israel Biotech Investment Fund (GIBF).
- When did CorNeat Vision's synthetic cornea receive approval for first-in-human implantation?
- CorNeat Vision's synthetic cornea was approved for first-in-human implantation in July 2020.